-transparent.png){kind=logo}
Fourteen previously untreated patients with metastatic small cell lung carcinoma (SCLC) were treated with carboplatin, 400 mg/m2, given as a 1-hour infusion every 28 days. Eleven patients had a partial response to therapy [response rate, 79% (95% confidence limits, 57%-100%)]. The median duration of response was 8 weeks (range, 4-41) and the median survival was 29 weeks (range, 11-68+). Hematologic toxicity was limited to one patient who developed World Health Organization (WHO) grade IV thrombocytopenia; no patient developed infection due to granulocytopenia. Nonhematologic toxicity was limited to WHO grade I and II nausea and vomiting. This study demonstrates that carboplatin is a highly active drug in SCLC with minimal toxicity. Future studies should evaluate its use in combination with other chemotherapeutic drugs in SCLC.
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
June 1991,
Cancer,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
May 2006,
British journal of cancer,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
December 2004,
Cancer chemotherapy and pharmacology,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
September 2014,
Cancer chemotherapy and pharmacology,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
January 2005,
Medical oncology (Northwood, London, England),
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
November 2001,
Lung cancer (Amsterdam, Netherlands),
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
June 2017,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
January 1990,
Cancer chemotherapy and pharmacology,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
December 2008,
British journal of cancer,
R H Jacobs, and
J D Bitran, and
M Deutsch, and
P C Hoffman, and
J Sinkule, and
S Purl, and
H M Golomb
January 1996,
Investigational new drugs,
